Raju Thomas, MD
Urology · New Orleans, LANPI 1093809360
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (59.3%), grants and consulting fees — rather than concentrated in one kind of arrangement. Olympus Corporation Of The Americas accounts for 63.0% of it on its own, with 38 other manufacturers making up the rest. Among urology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $377.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$42K
- KARL Storz Endoscopy-america$10K
- Gyrus ACMI, Inc.$7K
- Intuitive Surgical$2K
- Boston Scientific$745
- Astellas Pharma US Inc$488
- plus $3K from 33 others
Across 20 payments — averaging $4790.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$60K
- Janssen Research & Development, LLC$36K
What the payments were for
- Consulting fees$7,29011%
- Grants$10,00015%
- Travel & lodging$4,7317%
- Food & beverage$5,1638%
- Education$39,61459%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 56 | $42,095 |
| KARL Storz Endoscopy-america | 4 | $10,330 |
| Gyrus ACMI, Inc. | 5 | $7,331 |
| Intuitive Surgical | 20 | $2,393 |
| Boston Scientific | 15 | $745 |
| Astellas Pharma US Inc | 8 | $488 |
| Johnson & Johnson(2 entities) | 6 | $464 |
| Coloplast | 8 | $338 |
| Cook Medical LLC | 3 | $227 |
| Olympus America Inc. | 3 | $225 |
| Urogen Pharma, Inc. | 3 | $220 |
| Procept Biorobotics Corporation | 1 | $166 |
| Covidien LP | 1 | $161 |
| Teleflex LLC | 2 | $160 |
| Dendreon Pharmaceuticals LLC | 3 | $140 |
| Novartis | 1 | $127 |
| Medtronic | 1 | $120 |
| Progenics Pharmaceuticals, Inc. | 2 | $114 |
| Angiodynamics, Inc. | 1 | $110 |
| Conmed Corporation | 1 | $109 |
| Koelis Inc. | 1 | $79 |
| Merck | 3 | $62 |
| Ferring Pharmaceuticals Inc. | 2 | $57 |
| Pfizer | 3 | $57 |
| Innovation Technologies Inc | 1 | $56 |
| AstraZeneca | 1 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Endo USA, Inc. | 2 | $46 |
| Endo Pharmaceuticals Inc. | 2 | $42 |
| Sanofi | 2 | $37 |
| Photocure Inc | 1 | $31 |
| Bluewind Medical | 1 | $28 |
| Profound Medical Corp. | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| LSI Solutions Inc | 1 | $22 |
| Myovant Sciences Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 6 | $15 |
| Civco Medical Instruments | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Olympus Cystoscopes$17,980
- ShockPulse - SE$17,980
- VISERA ELITE$17,980
- Gyrus ACMI$12,933
- UroPass$12,933
- URETERO-RENO FIBERSCOPE$12,586
- N/A$10,000
- Olympus Stone Baskets and Retrievers$9,315
- Olympus Laser Devices$7,435
- Da Vinci Surgical System$1,860
- CYSTO-NEPHRO VIDEOSCOPE$400
- Monarch Platform$397
- JELMYTO$169
- AQUABEAM SYSTEM$166
- VISIGLIDE$162
- LigaSure$161
- TITAN$149
- CUTTING LOOP, BIPOLAR, 24/26 FR.$138
- URETERO-RENOSCOPE, 7FR X 43 CM, ACLAV$127
- LithoVue$126
How this compares
$66,798 in reported general payments places this provider in the 95th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 33 | $14,889 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 59 | $1,156 |
| Tamsulosin Hcl | 48 | $357 |
| Finasteride | 20 | $152 |
| Ciprofloxacin Hcl | 25 | $103 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $488 | $14,88933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 199 urology providers in Louisiana.
Other urology in New Orleans
- Richard VanlangendonckNew Orleans$289K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Louis KraneNew Orleans$62K
- Jorge CasoNew Orleans$54K
- Lawrence JenkinsNew Orleans$33K
- Alexis ChesrowNew Orleans$17K
- Joanna TogamiNew Orleans$10K
- Neil BaumNew Orleans$9K
- Kyle RoseNew Orleans$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.